No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists.
The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it.
Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity.
Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55–1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were .90 and .85. However, items lacked conceptual alignment with previously published factor structures.
Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure.
The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.
Author Affiliations: University of Michigan School of Nursing (Drs Smith and Yang and Ms Bridges); Institute for Healthcare Policy & Innovation, University of Michigan (Ms Banerjee), Ann Arbor; University of Milano-Bicocca (Dr Alberti), Italy; Alliance Statistics and Data Center (Dr Sloan), and Mayo Clinic (Dr Loprinzi), Rochester, Minnesota.
Research reported in this publication was supported by the National Cancer Institute of the National Institute of Health under award numbers UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), U10CA180790, and R03 CA186183-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The authors have no conflicts of interest to disclose.
Correspondence: Ellen M. Lavoie Smith, PhD, University of Michigan School of Nursing, 400 N Ingalls, Ann Arbor, MI 648109 (email@example.com).
Accepted for publication January 25, 2018.